Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now?

Area of Science:

• Hepatocellular carcinoma (HCC) research
• Oncology
• Drug development

Background:

• Hepatocellular carcinoma (HCC) incidence is rising globally, making it a significant health concern.
• Advanced HCC treatment has historically lacked effective systemic agents, with modest benefits from current therapies.
• There is a critical unmet medical need for novel treatments for HCC patients.

Purpose of the Study:

• To review current data on rational drug development for Hepatocellular carcinoma (HCC).
• To discuss the role of molecular targets and patient selection in advancing HCC treatment.
• To cover systemic agents for both front-line and previously treated HCC patients.

Main Methods:

• Review of basic and translational science identifying molecular targets in HCC.
• Analysis of clinical development of novel systemic agents for HCC.
• Evaluation of patient selection strategies based on clinical stage and predictive markers.

Main Results:

• Sorafenib studies showed modest survival benefits, highlighting the need for better therapies.
• Numerous potential molecular targets for HCC have been identified through basic research.
• Clinical development of targeted agents for HCC is actively progressing.

Conclusions:

• Successful development of targeted therapies for HCC depends on effective patient stratification.
• Future HCC treatment strategies will likely involve personalized approaches based on molecular profiles.
• Continued research into molecular targets and predictive markers is crucial for improving HCC patient outcomes.